Features Capital

Jenny Barba and Jeff Chu, the firm’s co-founders and managing partners, jointly lead investment decisions. Barba brings over $4 billion in healthcare-transaction experience and is a Kauffman Fellow; Chu is a medical-device inventor with 16 patents and extensive product-development work across more than 100 companies. The firm’s website presents them as the two principals driving both selection and portfolio support.

Features Capital operates as a private equity asset manager, not a family office. It raises and deploys capital specifically for early-stage MedTech investments. The firm’s structure — a specialized investment manager backed by its two named co-founders — aligns it more closely with a domain-focused micro-VC than with a wealth-consolidation vehicle.

The firm explicitly targets early-stage MedTech companies, focusing on pre-clinical and pre-revenue startups that need to reach first-in-human clinical validation or initial commercial revenue. Its portfolio positioning suggests it is comfortable writing the first institutional check, often as a company is approaching a regulatory milestone or bench-to-bedside translation.

Portfolio companies and operating founders span both the United States and Israel, indicating a transatlantic deal-sourcing pattern in MedTech. At least one confirmed portfolio company, OCON Therapeutics, is based in Israel (the firm’s website quotes former CEO Keren Leshem). The firm itself operates from New Hampshire.

The firm relies on a proprietary four-point vetting framework — evaluating product–market fit, scalability, and clinical opportunity — coupled with the co-founders’ networks in clinical engineering, product development, and healthcare finance. Publicly cited founder testimonials emphasize a thorough diligence process and deep structural-heart-market knowledge, suggesting sourcing is relationship-driven rather than inbound or data-mined.